Cemdisiran, a small interfering RNA drug that Regeneron Pharmaceuticals licensed from Alnylam Pharmaceuticals, met the goals of its pivotal test in generalized myasthenia gravis. The rare neuromuscular disease has several new therapies, but analysts see cemdisiran as having advantages over one particular class of drugs.
The post Regeneron’s RNA Med for Muscle Disease Meets Trial Goals; FDA Filing Planned for Next Year appeared first on MedCity News.
